Plaintiff
1 case as plaintiff.
Merus N.V. (Merus) is a biotechnology company headquartered in Utrecht, The Netherlands, with a U.S. office in Cambridge, Massachusetts. Founded in 2003, Merus was publicly traded on the Nasdaq Global Market under the ticker MRUS until its acquisition by Genmab A/S in December 2025 for approximately $6.9 billion. Merus now operates as a subsidiary of Genmab Holding II BV. As of April 2026, the company had around 261 employees and reported annual revenue of approximately $36.1 million in 2024, primarily from collaborations.
Merus is a clinical-stage oncology company focused on developing innovative full-length human bispecific and trispecific antibody therapeutics for the treatment of cancer. Its proprietary Multiclonics®, Biclonics®, and Triclonics® platforms are used to engineer multispecific antibodies designed to bind to multiple disease targets simultaneously. The company's pipeline includes drug candidates such as petosemtamab (MCLA-158), currently in Phase 3 trials for head and neck cancer, and zenocutuzumab (MCLA-128) for NRG1 fusion-positive cancers. Merus also has collaborations with other pharmaceutical companies, including Gilead Sciences.
Merus exhibits an active two-way patent litigation posture, appearing as a plaintiff in one tracked case and as a defendant in one. The company initiated a patent infringement lawsuit against Xencor, Inc. in the Delaware District Court on August 5, 2024. In this case, Merus N.V. v. Xencor, Inc., Merus alleges infringement of patents related to heterodimeric antibodies and methods for obtaining an antibody, specifically regarding Xencor's XmAb bispecific platform.
Concurrently, Xencor, Inc. filed a proceeding against Merus N.V. at the Patent Trial and Appeal Board (PTAB) on February 10, 2025. This PTAB action by Xencor is likely an inter partes review (IPR) challenging the validity of one or more of Merus's patents, potentially those asserted in the Delaware litigation. In the Delaware case, Xencor filed a motion to dismiss, arguing its activities were protected by the Hatch-Waxman safe harbor.
Watchlist
Email-only, free, anonymous. We'll notify you when Merus N.V. files another patent-infringement lawsuit. One-click unsubscribe from any alert.
The U.S. District Court for the District of Delaware granted defendant Xencor's motion to dismiss an infringement suit, holding that the accused use of Merus N.V.'s patented antibody technology was protected by the Hatch-Waxman safe harbor.